Related Experiment Video
Updated: Dec 12, 2025

Adenoviral Transduction of Naive CD4 T Cells to Study Treg Differentiation
Published on: August 13, 2013
Effect of brincidofovir on adenovirus and A549 cells transcriptome profiles
Maud Salmona1, Linda Feghoul2, Séverine Mercier-Delarue2
1Université de Paris, INSERM U976, Insight Team, F-75010, Paris, France; Assistance-Publique des Hôpitaux de Paris, Microbiology Department, Virology Unit, Saint Louis Hospital, F-75010, Paris, France.
Objectives:
Human adenovirus (HAdV) infections are associated with a high morbidity and mortality in transplant patients requiring the use of antiviral treatments. Brincidofovir (BCV), a cytidine analog, inhibits HAdV replication through viral DNA elongation termination and likely through other mechanisms. To elucidate if BCV regulates cellular antiviral pathways, we analyzed its impact on HAdV-infected and non-HAdV-infected lung epithelial cells.
Methods:
We assessed the cellular and viral transcriptome of A549 cells infected and non-infected with HAdV C5 and treated or non-treated with BCV by RNAseq after 72 h.
Results:
BCV treatment of HAdV infected cells resulted in a profound decrease of viral transcription associated with a relative overexpression of the early genes E1A and E4 and of the late gene L1. BCV had also a profound impact on A549 cells' transcriptome. Ontologic analysis revealed an effect of BCV on several pathways known to interact with adenovirus replication as mTor signalling and Wnt pathways. A549 cells treated with BCV demonstrated a significant inhibition of the biological function of "viral replication" including 25 dysregulated genes involved in inflammation pathways.
Conclusion:
We demonstrated that BCV alters viral gene expression and promotes the expression of antiviral cellular pathways in A549 cells. These results provide new insights how to interfere with cellular pathways to control HAdV infections.
Insights
Brincidofovir (BCV) reduces human adenovirus (HAdV) replication and alters viral gene expression. This antiviral treatment also enhances cellular antiviral pathways, offering new strategies for controlling HAdV infections.
Area of Science:
- Virology
- Molecular Biology
- Immunology
Background:
- Human adenovirus (HAdV) infections pose significant risks, especially in transplant patients, necessitating effective antiviral therapies.
- Brincidofovir (BCV), a cytidine analog, is an antiviral agent that inhibits HAdV replication.
- The precise mechanisms by which BCV impacts host cellular antiviral responses remain incompletely understood.
Purpose of the Study:
- To investigate the effects of Brincidofovir (BCV) on cellular antiviral pathways in the context of Human Adenovirus (HAdV) infection.
- To analyze the impact of BCV on the transcriptome of both HAdV-infected and non-infected lung epithelial cells.
Main Methods:
- RNA sequencing (RNAseq) was employed to assess the cellular and viral transcriptome.
- A549 lung epithelial cells were infected with HAdV C5 and treated with or without BCV for 72 hours.
- Bioinformatic analysis, including ontologic analysis, was performed on the obtained transcriptomic data.
Main Results:
- BCV treatment significantly reduced viral transcription in HAdV-infected cells, with notable changes in early (E1A, E4) and late (L1) gene expression.
- BCV profoundly impacted the host cell transcriptome, affecting pathways like mTOR signaling and Wnt pathways.
- BCV treatment inhibited the biological function of viral replication and modulated 25 genes involved in inflammation.
Conclusions:
- Brincidofovir (BCV) demonstrably alters viral gene expression and upregulates cellular antiviral pathways in lung epithelial cells.
- These findings provide novel insights into targeting cellular pathways for the effective control of Human Adenovirus (HAdV) infections.
Related Concept Videos
Viruses with RNA Genomes
Subviral Agents
Retroviruses
RNA Interference
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...

